Genetic testing companies have come under fire lately for an array of reasons. Many direct-to-consumer outfits are being challenged by the federal regulatory authorities, by the physicians' community and by the public itself. The desire to derive utility from the existing mass of genetic...

Large pharmaceutical companies (Multinational Pharmaceutical Companies or MPCs) have struggled in recent years with the rapidly accelerating costs of drug-discovery research and development. These costs continue to rise while resulting in fewer drug leads. Several industries have realized...

Valuing medical device companies and technologies is a complex process. Several different approaches and models are often used in combination to determine a transaction valuation. This research uses the Enterprise Value to Forward Sales model as a tool for valuing mergers and acquisitions in the...

It has been widely reported that pharmaceutical drug discovery innovation began its major decline somewhere in the last decade of the 20th century. After reaching a historical high of 53 new molecular entities (NMEs) in 1996, the industry has since witnessed a steady decline of NME filings (down...

Mergers and acquisitions in the Medical Device Industry are the primary mode of exit for early stage companies. The focus of this thesis is to examine factors which influence the value of these M&A transactions from the target and acquiring firm perspectives and to understand the value creation...

For a growing number of indications, combination therapies are becoming increasingly common due in part to their superior efficacy, as compared to monotherapies. In fact, in the case of infectious diseases such as AIDS and tuberculosis, combination therapies are now the standard of care. With...

The aim of this thesis was to look at the impact of acquiring the CE marking approval on the outcome of early stage medical device companies, specifically its impact on strategic acquisition opportunities and on valuation. We gathered data on acquisitions of 237 companies over the past ten...

Many early-stage biotech companies face a significant funding gap when trying to develop a new drug from preclinical development to a proof of concept clinical trial. This funding gap is sometimes referred to as the "valley of death", a reflection of the vast number of companies that are unable...

Venture capital investment performance data and performance attribution are not typically published. Venture investors articulate (and sell to LPs) conflicting strategies; the popular business literature and culture is rife with rapidly changing beliefs about the relative attractiveness of...

This thesis is part of a larger body of research being undertaken by Dr. Fiona Murray and colleagues examining value creation and sharing between and among the three principal players in the commercialization of academic biomedical research: universities, biotech firms, and big pharma. The...